Form 4: FibroGen CEO Wettig Thane Reports Stock Transaction
SEC Form 4 Filing
CEO Wettig Thane of FibroGen, Inc. reports disposition of shares to cover tax obligations.
Summary
- On June 22, 2024, Wettig Thane, CEO of FibroGen, Inc., reported a transaction involving the company's common stock.
- 782 shares were disposed of at a price of $1.13 to cover tax obligations related to the vesting of restricted stock units.
- Following the transaction, Wettig Thane directly owns 445,519 shares of FibroGen common stock.
- Additionally, Wettig Thane indirectly owns 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a small number of shares being sold to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 06/22/2024 | Date of stock transaction |
| 06/25/2024 | Date of signature by Attorney-in-Fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.